The Europe Influenza Market size is expected to reach USD 1.99 billion by 2025 from USD 1.27 billion in 2020, growing at a CAGR of 9.52% during the forecast period.
Influenza or flu is a transmittable respiratory disease that affects the nose, throat, and lungs. Influenza viruses are basically three types: A (H1N1, H2N2, and H5N1, etc.), Type B, and Type C. It can be either seasonal, pandemic, or zoonotic. Influenza can be fatal if it goes unnoticed and is regarded as a major reason for mortality globally. Some of the influenza symptoms are fever, cough, sore throat, runny or stuffy nose, fatigue, headache, and body ache. Children below 2 years of age and elderly above 65 are at high risk of developing chronic flu. As per a recent report, many older people in Europe were severely infected by the influenza virus in 2014-2015, resulting in a huge loss of human lives.
The market's growth is majorly driven by factors such as a boost in Research & Development investment, rising public awareness, the boost in healthcare expenditure, and the introduction of new medicines.
The key restraints of the market are the antigenic shift of the influenza virus and side-effects of the product (soreness, allergic reactions, swelling, and redness).
This research report on the European Influenza Market has been segmented and sub-segmented into the following categories:
By Product Type:
By Type:
By Application:
By Disease Indications:
By Country:
Some of the notable companies dominating the European Influenza Market are Sanofi-Pasteur (U.S.), AstraZeneca (United Kingdom), F. Hoffmann-La Roche (Switzerland), Novartis (Switzerland), GlaxoSmithKline (U.K.), Pfizer Inc. (U.S.), Merck & Co. (U.S.), Abbott Laboratories (U.S.), Mitsubishi Tanabe Pharma Corporation (Japan), CSL Limited (Australia).
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Product Type
5.1.1 Introduction
5.1.2 Vaccines
5.1.3 Drugs
5.1.4 Y-o-Y Growth Analysis, By Product
5.1.5 Market Attractiveness Analysis, By Product
5.1.6 Market Share Analysis, By Product
5.2 Type
5.2.1 Introduction
5.2.2 Safety Biomarkers
5.2.3 Efficacy Biomarkers
5.2.4 Validation Biomarkers
5.2.5 Y-o-Y Growth Analysis, By Type
5.2.6 Market Attractiveness Analysis, By Type
5.2.7 Market Share Analysis, By Type
5.3 Application
5.3.1 Introduction
5.3.2 Diagnostics Development
5.3.3 Drug Discovery and Development
5.3.4 Personalised Medicine
5.3.5 Disease Risk Assessment
5.3.6 Other Applications
5.3.7 Y-o-Y Growth Analysis, By Application
5.3.8 Market Attractiveness Analysis, By Application
5.3.9 Market Share Analysis, By Application
5.4 Disease Indications
5.4.1 Introduction
5.4.2 Cancer
5.4.3 CardiovascularDisorders
5.4.4 Neurological Disorders
5.4.5 Immunological Disorders
5.4.6 Other Diseases
5.4.7 Y-o-Y Growth Analysis, By Disease Indications
5.4.8 Market Attractiveness Analysis, By Disease Indications
5.4.9 Market Share Analysis, By Disease Indications
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Product
6.1.3.3 By Type
6.1.3.4 By Application
6.1.3.5 By Indication
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Product
6.1.4.3 By Type
6.1.4.4 By Application
6.1.4.5 By Indication
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Product
6.1.5.3 By Type
6.1.5.4 By Application
6.1.5.5 By Indication
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Sanofi-Pasteur
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 AstraZeneca
8.3 F. Hoffmann-La Roche
8.4 Novartis
8.5 GlaxoSmithKline
8.6 Pfizer Inc.
8.7 Merck & Co.
8.8 Abbott Laboratories
8.9 Mitsubishi Tanabe Pharma Corporation
8.10 CSL Limited
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Feb 2020
